Physician profile
Mark J Geller
NPI 1396709069
$5,452.06
in general payments reported to CMS, 2019-2025
30 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $916 · 2021: $1,262 · 2022: $715 · 2023: $704 · 2024: $551 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,231.20 | 2019-2024 | Xarelto |
| Amgen INC. | $1,066.94 | 2019-2025 | Repatha, Prolia, Evenity |
| Merck Sharp & Dohme LLC | $522.92 | 2021-2024 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.32 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $380.66 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $341.08 | 2019-2025 | |
| Novo Nordisk INC | $259.70 | 2021-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $187.31 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $163.95 | 2022-2025 | |
| Lilly USA, LLC | $123.50 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Daiichi Sankyo INC. | $111.98 | 2020-2025 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $87.28 | 2019-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $76.60 | 2020-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $74.94 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $68.59 | 2023-2025 | Lifevest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $62.47 | 2019-2021 | |
| Cleerly, INC. | $37.50 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Lundbeck LLC | $35.78 | 2024 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $22.76 | 2025 | Uptravi |
| Allergan, INC. | $21.00 | 2019 | |
| Heartflow, INC. | $20.39 | 2025 | |
| Bracco Diagnostics INC. | $19.56 | 2022 | |
| Neurocrine Biosciences, INC. | $17.82 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.60 | 2024 | Voquezna |
| Indivior INC. | $14.83 | 2025 | Sublocade |
| Arbor Pharmaceuticals, INC. | $14.32 | 2020 | |
| Glaxosmithkline, LLC. | $13.73 | 2019 | |
| Boston Scientific Corporation | $13.38 | 2022 | |
| Exact Sciences Corporation | $13.31 | 2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.